Sugar can be linked to high blood glucose levels, obesity, diabetes, cardiovascular disease, Alzheimer's disease, macular degeneration, tooth decay, and addiction. Hence, sugar is worse or just as bad as tobacco. People who have these facts wouldn't argue against stevia, and combined with stevia's growth rate, it clearly appears that stevia is the future of sweeteners. STVF couldn't be more attractive
You're absolutely right.... If you look at stocks to be included in Russell index funds at any given year followed by their three month stock price, almost all outperform the market. Also, Russell is just one of the funds that may include NBS. There is a long line.
The good thing about STVF is that they are a research company of a commodity that doesn't have widespread use in the soda and food industry. Large beverage companies especially are showing a sense of desperation to cut down on calories,but must not sacrifice any taste. We'll see what happens from here but my initial thoughts are that STVF found something even better than what's currently in the market and in development.
Merck may have the very best single agent anti-PD1 in development, but as an investor I am really worried at their lack of pipeline development to combine MK-3475 with other inhibitors worries me. Read "Immune Checkpoint Blocker Race Heats Up" from yesterday, it paints a nice picture of the industry but after seeing what other companies have it worries me about Merck.
Merck will be late to the game behind BMY, and by the time it gets on the market, BMY will have Yervoy combined with Nivolumab. Then, there are smaller companies like Lion that have great technology to be combined. Any thoughts?